Search Results

You are looking at 111 - 120 of 476 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Donna Trauth and Lori J. Goldstein

1998 ; 17 : 101 . 65 Eifel P Axelson JA Costa J . National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3 2000 . J Natl Cancer Inst 2001 ; 93 : 979 . www

Full access

David S. Ettinger

fusion gene EML-4 ALK . This mutation seems to be mutually exclusive with the EGFR and KRAS mutation in the phase I study. Adjuvant Therapy In 2004, the International Adjuvant Lung Cancer Trial showed an approximately 5% survival advantage

Full access

Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea

should be tempered by maximal preservation of neurologic function. What does seem to be apparent is that STR without any adjuvant therapy is associated with a poor prognosis. There have been 16 cases presented in the literature that have undergone STR or

Full access

Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter

predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate

Full access

Ami Vyas, S. Suresh Madhavan, and Usha Sambamoorthi

months) after BC diagnosis constituted 37% of BC Medicare spending, which is substantially higher due to surgery and adjuvant therapy. 2 – 6 Additionally, elderly women aged ≥65 years have higher BC incidence compared with their younger counterparts, 7

Full access

Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin

different benefits were seen from adjuvant therapy. 64 Patients were followed for a median of 4 years, with 41% of patients administered fluoropyrimidine-based adjuvant therapy. Patients with intermediate tumor response benefited the most from adjuvant

Full access

Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger

was sufficient to warrant consideration of adjuvant chemotherapy. Because cancer was found to be the primary cause of death in this population, adjuvant therapy is likely to improve disease outcomes. The lower rates of adjuvant therapy use among

Full access

03689712) is in progress. Clinical trials to reduce RT-related esophagitis are also planned. CLO19-040: The Role of Adjuvant Therapy in Patients With Pathological T2N0 Resected Gastric Adenocarcinoma John Khoury, MD a ; David Macari, MD a ; Daniel Ezekwudo

Full access

William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar

experienced breast surgery team that works in a coordinated, multidisciplinary fashion to guide proper patient selection for skin-sparing mastectomy, determine optimal sequencing of the reconstructive procedures in relation to adjuvant therapies, and perform a

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski, and Deborah A. Freedman-Cass

. Preoperative chemoRT may result in tumor downsizing and a decrease in tumor bulk (see “Neoadjuvant and Adjuvant Therapy for Resectable Nonmetastatic Disease,” page 885); sphincter preservation may become possible in cases where initial tumor bulk prevented